Appl. No. 10/527,557 Amdt. dated June 28, 2010 Reply to Office Action of January 28, 2010

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

- 1-13. (Cancelled)
- 14. (Previously presented) A method of inhibiting the growth of Mycobacterium tuberculosis ("MTB"), the method comprising the step of introducing capreomycin into gases to be inhaled by a patient in need thereof.
- 15. (Previously presented) The method of claim 14, wherein the capreomycin is introduced into the gases as a solution, a suspension, a powder, or a spray.
- 16. (Previously presented) The method of claim 14, wherein the capreomycin introduced into the gases in an average particle size of between 1 and 10 microns.
- 17. (Previously presented) The method of claim 14, wherein the capreomycin is complexed or associated with a polysaccharide.
- 18. (Previously presented) The method of claim 14, wherein the capreomycin is introduced into the gases by a nebulizer, a metered dose inhaler, or a dry powder inhaler.
- 19. (Previously presented) The method of claim 18, wherein the nebulizer is selected from the group consisting of a heated nebulizer, an ultrasonic nebulizer, a gas nebulizer, a venturi nebulizer, and a refillable nebulizer.
- 20. (Previously presented) A method of inhibiting the growth of Mycobacterium tuberculosis ("MTB") in a patient, the method comprising the step of administering to a lung of the patient aerosolized capreomycin, wherein the capreomycin inhibits the growth of MTB in the patient.

Appl. No. 10/527,557 Amdt. dated June 28, 2010 Reply to Office Action of January 28, 2010

- 21. (Previously presented) The method of claim 20, wherein the capreomycin is administered to the lung as a solution, a suspension, a powder, or a spray.
- 22. (Previously presented) The method of claim 20, wherein the capreomycin is administered to said lung by a nebulizer, a metered dose inhaler, or a dry powder inhaler.
- 23. (Previously presented) The method of claim 22, wherein the nebulizer is selected from the group consisting of a heated nebulizer, an ultrasonic nebulizer, a gas nebulizer, a venturi nebulizer, and a refillable nebulizer.
- 24. (Previously presented) The method of reducing infectivity of a person infected with Mycobacterium tuberculosis ("MTB"), the method comprising the step of administering to the lung of the person aerosolized capreomycin, wherein the capreomycin reduces the infectivity of the person.
- 25. (Previously presented) The method of claim 24, wherein the capreomycin is administered to the lung as a solution, a suspension, a powder, or a spray.
- 26. (Previously presented) The method of claim 24, wherein the capreomycin is administered to the lung by a nebulizer, a metered dose inhaler, or a dry powder inhaler.
- 27. (Previously presented) The method of claim 26, wherein the nebulizer is selected from the group consisting of a heated nebulizer, an ultrasonic nebulizer, a gas nebulizer, a venturi nebulizer, and a refillable nebulizer.
 - 28-30. (Cancelled)